In short
Dinutuximab Beta, also known as ch14.18/CHO or Qarziba, is an innovative immunotherapy drug being studied in several clinical trials for the treatment of high-risk neuroblastoma and other cancers. This article explores the ongoing research into Dinutuximab Beta's efficacy, safety, and potential applications in various cancer types, including neuroblastoma, sarcomas, and leiomyosarcoma.
At a glance
- Primary Cancer Type
- High-risk neuroblastoma
- Other Cancer Types Studied
- Sarcomas, leiomyosarcoma, osteosarcoma
- Mechanism of Action
- Targets GD2 on cancer cells, enhancing immune system response
- Administration
- Intravenous infusion, typically over several days
- Common Side Effects
- Pain, fever, allergic reactions, changes in blood pressure
- Combination Therapies
- Often studied with chemotherapy, IL-2, GM-CSF, and other immunotherapies
- Key Outcome Measures
- Progression-free survival, overall survival, event-free survival, tumor response
- Current Status
- Approved in EU for certain high-risk neuroblastoma patients; in clinical trials for other indications
What is Dinutuximab Beta?
Dinutuximab Beta is a type of medicine called a monoclonal antibody. It's also known by other names such as ch14.18, Qarziba, and anti-GD2 antibody. This medication is designed to help your immune system fight certain types of cancer cells.
How Does it Work?
Dinutuximab Beta works by targeting a specific molecule called GD2, which is found on the surface of some cancer cells, especially neuroblastoma cells. When the antibody attaches to GD2, it "labels" the cancer cells, making them easier for your immune system to recognize and attack.
What Conditions Does it Treat?
Dinutuximab Beta is primarily used to treat a type of childhood cancer called neuroblastoma. Neuroblastoma is a cancer that starts in certain nerve cells, usually in young children. It's most commonly used for high-risk neuroblastoma, which means the cancer is more likely to come back after treatment.
Researchers are also studying its use in other types of cancers, including:
- Osteosarcoma: A type of bone cancer
- Leiomyosarcoma: A cancer that affects smooth muscle tissue
- Rhabdomyosarcoma: A cancer that develops in skeletal muscle tissue
- Ewing sarcoma: Another type of bone cancer
How is it Administered?
Dinutuximab Beta is given as an intravenous (IV) infusion, which means it's delivered directly into your bloodstream through a vein. The exact dosage and schedule can vary depending on the specific treatment plan and the patient's body size. Here are some common approaches:
- Continuous infusion over 10 days in a 35-day cycle
- Daily infusions for 5-10 consecutive days in a 4-week cycle
- For patients weighing more than 12 kg, the dose is often calculated based on body surface area (10 mg/m² per day)
- For patients weighing 12 kg or less, the dose may be based on body weight (0.33 mg/kg per day)
Ongoing Research
Scientists are currently studying Dinutuximab Beta in various clinical trials to learn more about its effectiveness and safety. Some areas of research include:
- Combining Dinutuximab Beta with other cancer treatments, such as chemotherapy drugs or other immunotherapy medications
- Using Dinutuximab Beta as a maintenance therapy to help prevent cancer from coming back after initial treatment
- Testing its effectiveness in different types of cancers that express the GD2 molecule
- Exploring different dosing schedules to maximize effectiveness and minimize side effects
Potential Side Effects
Like all medications, Dinutuximab Beta can cause side effects. Some of the most common or significant side effects reported in clinical trials include:
- Pain: This is one of the most common side effects and may require pain medication
- Allergic reactions: These can range from mild to severe and may require close monitoring
- Nerve problems: This can include changes in sensation or movement
- Fever: Many patients experience fever during treatment
- Changes in blood pressure: Both high and low blood pressure have been reported
- Gastrointestinal issues: This can include nausea, vomiting, or diarrhea
It's important to note that not everyone experiences these side effects, and your healthcare team will work to manage any side effects that do occur. Always report any unusual symptoms or side effects to your doctor promptly.